A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
about
Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia.MGCD0103 induces apoptosis and simultaneously increases the expression of NF-κB and PD-L1 in classical Hodgkin's lymphoma
P2860
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
A phase 2 study of mocetinosta ...... lapsed or refractory lymphoma.
@en
type
label
A phase 2 study of mocetinosta ...... lapsed or refractory lymphoma.
@en
prefLabel
A phase 2 study of mocetinosta ...... lapsed or refractory lymphoma.
@en
P2093
P2860
P356
P1476
A phase 2 study of mocetinosta ...... lapsed or refractory lymphoma.
@en
P2093
Amanda Copeland
Anas Younes
Charalambos Andreadis
Connie L Batlevi
David Rizzieri
Diane Potvin
Michael Crump
Richard Chao
Richard H C van der Jagt
Sarit E Assouline
P2860
P304
P356
10.1111/BJH.14698
P407
P577
2017-04-25T00:00:00Z